微观卫星网络是微观卫星不稳定性 (MSI) 的癌症的一个有希望的合成致命目标
Edmond M Chan1,2,3,4, Kyla J Foster5, Adam J Bass6
1Department of Medicine, Division of Hematology and Oncology, Columbia University, New York, USA. emc2291@cumc.columbia.edu.
Cancer treatment and research
|November 17, 2023
概括
微卫星不稳定性 (MSI) 癌症容易受到WRN蛋白质耗尽的影响. 这是因为MSI细胞积累了长时间的TA重复,形成了WRN通常解决的DNA结构,防止复制叉崩.
科学领域:
- 遗传学 遗传学 是一个
- 癌症生物学 癌症生物学
- 分子瘤学分子瘤学
背景情况:
- 微卫星不稳定性 (MSI) 是大约3%的人类癌症的遗传特征,源于缺陷的DNA不匹配修复 (MMR).
- 根据临床前发现,RecQ酶WRN已经成为MSI癌症中潜在的合成致命标.
研究的目的:
- 调查MSI癌细胞中WRN耗尽时观察到的合成致死性背后的机制.
- 为了阐明TA二核酸重复扩张在驱动这种合成致命表型中的作用.
主要方法:
- 在MSI和微卫星稳定 (MSS) 癌细胞系中减少WRN蛋白.
- 分析细胞活力和DNA复制叉的动态.
- 评估TA二核酸重复长度和二次DNA结构的形成.
主要成果:
- 虽然WRN枯竭显著降低了MSI细胞的活力,但对MSS细胞的影响很小.
- MSI细胞表现出扩大TA二核酸重复的增加积累.
- 这些扩展的重复被发现形成了依赖于WRN解析的二次DNA结构.
- 在没有WRN的情况下,未解决的DNA二次结构导致了停滞的复制分叉和DNA损伤.
结论:
- WRN枯竭和MSI之间的合成致命相互作用是由扩展的TA重复的积累驱动的.
- WRN对于在MSI细胞中由这些重复形成的二次DNA结构的解决至关重要,从而防止复制压力和基因组不稳定性.
更多相关视频
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
4.2K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.6K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
MicroRNAs
21.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.3K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Mismatch Repair
4.9K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.9K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
